AstraZeneca to Recover Global Rights to Brazikumab From Allergan

Date : 01/27/2020 @ 7:48AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 44.66  0.13 (0.29%) @ 1:00AM
After Hours
Last Trade
Last $ 44.66 ◊ 0.00 (0.00%)

AstraZeneca to Recover Global Rights to Brazikumab From Allergan

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Jan 2020 to Apr 2020

Click Here for more Astrazeneca Charts.
   By Ian Walker 

AstraZeneca PLC (AZN.LN) said Monday that it will take back the global rights to brazikumab after ending a license deal with Allergan PLC (AGN).

AstraZeneca said Allergen will fund the costs of developing brazikumab, which is used for Crohn's disease and ulcerative colitis.

The transaction is expected to complete in the first quarter of this year, subject to regulatory approvals associated with AbbVie Inc.'s (ABBV) proposed acquisition of Allergan, AstraZeneca said.


Write to Ian Walker at


(END) Dow Jones Newswires

January 27, 2020 02:33 ET (07:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.